share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bhatia Sangeeta N.

SEC announcement ·  May 3 16:10
Summary by Moomoo AI
Sangeeta N. Bhatia, associated with Vertex Pharmaceuticals Inc. (VRTX), completed a sale of company stock on May 2, 2024. The transaction involved the disposal of 467 shares of common stock at a price of $402.95 per share, resulting in a total market value of $188,177.65. This sale followed an acquisition of 1,001 shares on May 1, 2024, which were granted at no cost. After these transactions, Bhatia's direct holdings in Vertex Pharmaceuticals totaled 4,435 shares. The sale took place in the open market and is part of the normal course of stock trading for company insiders.
Sangeeta N. Bhatia, associated with Vertex Pharmaceuticals Inc. (VRTX), completed a sale of company stock on May 2, 2024. The transaction involved the disposal of 467 shares of common stock at a price of $402.95 per share, resulting in a total market value of $188,177.65. This sale followed an acquisition of 1,001 shares on May 1, 2024, which were granted at no cost. After these transactions, Bhatia's direct holdings in Vertex Pharmaceuticals totaled 4,435 shares. The sale took place in the open market and is part of the normal course of stock trading for company insiders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more